Furthermore, improved imaging in patients with prolonged survival due to the using of targeted systemic therapies in NSCLC with EGFR mutation is associated with a higher incidence of BM along with the disease process [5]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.